Company news

Minerva Neurosciences, Inc news in 2026

Minerva Neurosciences, Inc's news releases, calls and decks from 2026, newest first.

View company

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

October 29, 2026

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

October 28, 2026

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

August 28, 2026

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

August 7, 2026

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

June 1, 2026

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 18, 2026

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026

Minerva Announces Leadership Transition

April 1, 2026

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

March 30, 2026

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

March 25, 2026

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

March 12, 2026

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

March 10, 2026

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

March 3, 2026

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

January 26, 2026

Decks in 2026